Dijon

• Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc … Ended
  2024-515533-15-00 4 Locally advanced cervical cancer
• Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA Ended
  2024-516028-33-01 5 HIV infection
• Trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer Ended
  2024-516558-24-00 4 Pancreatic (PAAD)
• Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended
  2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b
• LONG-TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AN … Ended
  2024-517925-25-00 4 prader-willi syndrome
• PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended
  2024-519258-35-00 4 stomach cancer
• A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended
  2024-519671-26-00 9 Advanced or Metastatic Non-Small Cell Lung Cancer
• A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies Ended
  2025-521600-21-00 1 mature B-Cell malignancies
• A multicentric phase II trial evaluating volrusotmig in patients with mature tertiary lymphoid structures solid tumors. Expired
  2023-503451-94-00 4 Adult participants with metastatic (advanced) solid tumors

Showing 817–825 of 825 trials